Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet's disease, National multicenter study of 177 cases

Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients

Clin Immunol.

Desbois AC, Biard L, Addimanda O, Lambert M, Hachulla E, Launay D, Ackerman F, Pérard L, Hot A, Maurier F, Mausservey C, Bernard F, Noel N, Alric L, Mirault T, Cohen F, Boussouar S, Resche-Rigon M, Cacoub P, Saadoun D

doi: 10.1016/j.clim.2018.08.004.

Rheumatoid Arthritis

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study

Medicine (Baltimore)

Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondo K, Ishigatsubo Y

doi: 10.1097/

Psoriatic Arthritis

Treatment with tofacitinib in refractory psoriatic arthritis. National multicenter study of the first 87 patients of clinical practice

J Rheumatol

Galíndez-Agirregoikoa E, Prieto-Peña D, Martín-Varillas JL, Joven B, Rusinovich O, Melero-González RB, Ortiz-Sanjuan F, Almodóvar R, Alegre JJ, Martínez Á, Sellas-Fernández A, Méndez L, García-Vicuña R, Atienza-Mateo B, Gorostiza I, González-Gay MÁ, Blanco R, Tofacitinib PsA Clinical Practice Collaborative Group.

doi: 10.3899/jrheum.201204

Rheumatoid ArthritisFurther Publications Rheumatology

Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial

Ann Rheum Dis

Nabi H, Georgiadis S, Loft AG, Hendricks O, Andersen M, Chrysidis S, Colic A, Danebod K, Hussein MR, Kalisz MH, Kristensen S, Lomborg N, Manilo N, Munk HL, Pedersen JK, Raun JL, Mehnert F, Krogh NS, Hetland ML, Glintborg B

doi: 10.1136/annrheumdis-2021-219951

Rheumatoid Arthritis

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison

RMD Open.

Fautrel B, Zhu B, Taylor PC, van de Laar M, Emery P, De Leonardis F, Kannowski CL, Nicolay C, Kadziola Z, De La Torre I, Fleischmann R

doi: 10.1136/rmdopen-2019-001131.

Rheumatoid Arthritis

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

Ann Rheum Dis.

Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME

doi: 10.1136/

Rheumatoid Arthritis

ABATACEPT IN MONOTHERAPY VERSUS COMBINED IN INTERSTITIAL LUNG DISEASE OF RHEUMATOID ARTHRITIS. MULTICENTER STUDY OF 263 CAUCASIAN PATIENTS

Rheumatology (Oxford)

Fernández-Díaz C, Atienza-Mateo B, Castañeda S, Melero-Gonzalez RB, Ortiz-SanJuan F, Loricera J, Casafont-Solé I, Rodríguez-García S, Aguilera-Cros C, Villa-Blanco I, Raya-Alvarez E, Ojeda-García C, Bonilla G, López-Robles A, Arboleya L, Narváez J, Cervantes E, Maiz O, Alvarez-Rivas MN, Cabezas I, Salgado E, Hidalgo-Calleja C, Fernández S, Fernández JC, Ferraz-Amaro I, González-Gay MA, Blanco R, Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis.

doi: 10.1093/rheumatology/keab317

Psoriatic Arthritis

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

Ann Rheum Dis.

Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratacós J, Goupille P, Liu Leage S, Pillai S, Nash P

doi: 10.1136/annrheumdis-2020-217372.

Autoimmune Disease

Epigenome-Wide Comparative Study Reveals Key Differences Between Mixed Connective Tissue Disease and Related Systemic Autoimmune Diseases

Front Immunol.

Carnero-Montoro E, Barturen G, Povedano E, Kerick M, Martinez-Bueno M, PRECISESADS Clinical Consortium., Ballestar E, Martin J, Teruel M, Alarcón-Riquelme ME

doi: 10.3389/fimmu.2019.01880.

Related content

Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study

Treatment with tofacitinib in refractory psoriatic arthritis. National multicenter study of the first 87 patients of clinical practice

Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

ABATACEPT IN MONOTHERAPY VERSUS COMBINED IN INTERSTITIAL LUNG DISEASE OF RHEUMATOID ARTHRITIS. MULTICENTER STUDY OF 263 CAUCASIAN PATIENTS

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

Epigenome-Wide Comparative Study Reveals Key Differences Between Mixed Connective Tissue Disease and Related Systemic Autoimmune Diseases